Spencer D. Brown - Jun 2, 2022 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role: Senior VP, General Counsel
Signature: /s/ Matthew C. Hill, as Attorney-in-Fact
Stock symbol: PDSB
Transactions as of: Jun 2, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/3/2022, 08:20 AM
Previous filing: Jun 3, 2022
Next filing: Jan 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PDSB	Employee Stock Option (Right to Buy)	Award	$0	+150K		$0.00	150K	Jun 2, 2022	Common Stock	150K	$4.22	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. This option, representing a right to purchase a total of 150,000 shares of Common Stock, will become exercisable on June 2, 2023, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.

Content

This option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. This option, representing a right to purchase a total of 150,000 shares of Common Stock, will become exercisable on June 2, 2023, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.